Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles.

In an effort to develop an alternative formulation of paclitaxel suitable for parenteral administration, paclitaxel-loaded sterically stabilized solid lipid nanoparticles (SLNs) were prepared, characterized and examined for in vitro cytotoxicity. The SLNs, comprising trimyristin (TM) as a solid lipid core and egg phosphatidylcholine and pegylated phospholipid as stabilizers, were prepared using a hot homogenization method. Regardless of paclitaxel loading, the particle sizes and zeta potentials of the prepared SLNs were around 200nm and -38mV, respectively, suggesting that they would be suitable as a parenteral formulation. Cryo-scanning electron microscopy showed that the SLNs were homogeneous and spherical in shape, while differential scanning calorimetry measurement of the melting peak revealed that the TM exists as a solid in our formulation. Paclitaxel was loaded to the solid cores at a w/w ratio of 6%. Gel column chromatography showed that paclitaxel co-eluted with the phospholipids, indicating that paclitaxel was incorporated in the SLNs. An in vitro drug release study showed that paclitaxel was released from the SLNs in a slow but time-dependent manner. Furthermore, treatment of the OVCAR-3 human ovarian cancer cell line and the MCF-7 breast cancer cell line with paclitaxel-loaded SLNs yielded cytotoxicities comparable to those of a commercially available Cremophor EL-based paclitaxel formulation. These results collectively suggest that our optimized SLN formulation may have a potential as alternative delivery system for parenteral administration of paclitaxel.

[1]  Simon Benita,et al.  Microencapsulation : methods and industrial applications , 1996 .

[2]  G. Hortobagyi,et al.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[3]  K. Westesen,et al.  Physicochemical characterization of a model intravenous oil-in-water emulsion. , 1992, Journal of pharmaceutical sciences.

[4]  R. Perez-soler,et al.  Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report. , 1994, Journal of microencapsulation.

[5]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization , 1994 .

[6]  K M Park,et al.  Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. , 1999, International journal of pharmaceutics.

[7]  R. Müller,et al.  Biodegradation of solid lipid nanoparticles as a function of lipase incubation time , 1996 .

[8]  H. Burt,et al.  Development of a Polymeric Surgical Paste Formulation for Taxol , 1996, Pharmaceutical Research.

[9]  J C Stewart,et al.  Colorimetric determination of phospholipids with ammonium ferrothiocyanate. , 1980, Analytical biochemistry.

[10]  D. L. Gilbert,et al.  Compatibility and Stability of Paclitaxel Combined with Cisplatin and with Carboplatin in Infusion Solutions , 1997, The Annals of pharmacotherapy.

[11]  R. Müller,et al.  Fat emulsions for parenteral nutrition II: Characterisation and physical long-term stability of Lipofundin MCT LCT. , 1993, Clinical nutrition.

[12]  M. Markman,et al.  Taxol: an important new drug in the management of epithelial ovarian cancer. , 1991, The Yale journal of biology and medicine.

[13]  F. Dosio,et al.  From Conventional to Stealth Liposomes: a New Frontier in Cancer Chemotherapy , 2004, Journal of chemotherapy.

[14]  S. Benita Submicron Emulsions in Drug Targeting and Delivery , 2019 .

[15]  T. Poon,et al.  Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. , 2005, In vivo.

[16]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[17]  M. K. Lee,et al.  Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. , 1999, International journal of pharmaceutics.

[18]  Gilbert S. Banker,et al.  Pharmaceutical Dosage Forms: Disperse Systems , 1988 .

[19]  D. L. Gilbert,et al.  Compatibility and Stability of Paclitaxel Combined with Doxorubicin Hydrochloride in Infusion Solutions , 1998, The Annals of pharmacotherapy.

[20]  S. Yalkowsky,et al.  A New Parenteral Emulsion for the Administration of Taxol , 1987, Pharmaceutical Research.

[21]  R. Straubinger,et al.  Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes , 1994, Pharmaceutical Research.

[22]  K. Westesen,et al.  Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles , 1997 .

[23]  R. Müller,et al.  Fat emulsions for parenteral nutrition. I: Evaluation of microscopic and laser light scattering methods for the determination of the physical stability. , 1992, Clinical nutrition.